[开放获取]  小分子靶向药物：银屑病治疗的新选择

doi:10.35541/cjd.20210630

Abstract

Abstract: 【Abstract】 With the rapid development of immunology and molecular biology in recent years, great progress has been made in the research on psoriatic pathogenesis, as well as in therapeutic strategies targeting key molecules in the pathogenesis. In addition to biologics, small-molecule targeted agents for psoriasis have also received increasing attention, especially agents targeting phosphodiesterase 4, Janus kinase, and tyrosine kinase 2, etc. An increasing number of small-molecule drug candidates have shown favorable efficacy in clinical studies, and some of them have been approved for clinical application and play a unique role in the treatment of psoriasis.

Key words: Psoriasis, Phosphodiesterase 4 inhibitors, Janus kinase inhibitors, Tyrosine kinase 2 inhibitors, Small molecules

Yu Chen, Wang Gang. Small-molecule targeted agents: new choices for the treatment of psoriasis[J]. Chinese Journal of Dermatology, 2022, 55(9): 747-751.doi:10.35541/cjd.20210630

References ［32］

［1］	Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review［J］. JAMA, 2020,323（19）:1945⁃1960. doi: 10.1001/jama.2020.4006.
［2］	Honma M, Hayashi K. Psoriasis: recent progress in molecular⁃targeted therapies［J］. J Dermatol, 2021,48（6）:761⁃777. doi:10. 1111/1346⁃8138.15727.
［3］	Ghoreschi K, Balato A, Enerbäck C, et al. Therapeutics targeting the IL⁃23 and IL⁃17 pathway in psoriasis［J］. Lancet, 2021,397（10275）:754⁃766. doi: 10.1016/S0140⁃6736（21）00184⁃7.
［4］	Balogh EA, Bashyam AM, Ghamrawi RI, et al. Emerging systemic drugs in the treatment of plaque psoriasis［J］. Expert Opin Emerg Drugs, 2020,25（2）:89⁃100. doi: 10.1080/14728214. 2020.1745773.
［5］	Grand D, Navrazhina K, Frew JW, et al. Research pipeline I: oral therapeutics for psoriasis//Weinberg JM, Lebwohl M. Advances in psoriasis: a multisystemic guide［M］. Cham, Switzerland:Springer, 2021:291⁃302. doi: 10.1007/978⁃3⁃030⁃54859⁃9_23.
［6］	Weisel K, Scott NE, Tompson DJ, et al. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers［J］. Pharmacol Res Perspect, 2017,5（6）:e00365. doi: 10.1002/prp2.365.
［7］	Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 （PDE4） inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial （Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis ［ESTEEM］ 1）［J］. J Am Acad Dermatol, 2015,73（1）:37⁃49. doi: 10.1016/j.jaad.2015.03.049.
［8］	Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate⁃to⁃severe plaque psoriasis: 52⁃week results from a phase IIIb, randomized, placebo⁃controlled trial （LIBERATE）［J］. J Eur Acad Dermatol Venereol, 2017,31（3）:507⁃517. doi: 10.1111/jdv. 14015.
［9］	Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate⁃to⁃severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial （ESTEEM 2）［J］. Br J Dermatol, 2015,173（6）:1387⁃1399. doi: 10.1111/bjd.14164.
［10］	Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis［J］. N Engl J Med, 2020,383（3）:229⁃239. doi: 10.1056/NEJMoa2000073.
［11］	Kvist⁃Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: a review［J］. Dermatol Ther （Heidelb）, 2020,10（1）:29⁃42. doi: 10.1007/s13555⁃019⁃00347⁃w.
［12］	Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo⁃controlled, phase III trials［J］. Br J Dermatol, 2015,173（4）:949⁃961. doi: 10.1111/bjd. 14018.
［13］	Zhang J, Tsai TF, Lee MG, et al. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a phase 3, randomized, double⁃blind, placebo⁃controlled study［J］. J Dermatol Sci, 2017,88（1）:36⁃45. doi: 10. 1016/j.jdermsci.2017.05.004.
［14］	Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate⁃to⁃severe chronic plaque psoriasis: a phase 3 randomised non⁃inferiority trial［J］. The Lancet, 2015, 386（9993）:552⁃561. doi: 10.1016/S0140⁃6736（14）62113⁃9.
［15］	Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase⁃signal transducer and activator of transcription signaling and inhibition in plaque psoriasis［J］. J Am Acad Dermatol, 2022,86（1）:148⁃157. doi: 10.1016/j.jaad.2021.06.869.
［16］	McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis［J］. N Engl J Med, 2021,384（13）:1227⁃1239. doi: 10.1056/NEJMoa2022516.
［17］	Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT⁃PsA 2［J］. Ann Rheum Dis, 2020,80（3）:312⁃320. doi: 10.1136/annrheumdis⁃2020⁃218870.
［18］	Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis［J］. N Engl J Med, 2018,379（14）:1313⁃1321. doi: 10.1056/NEJMoa1806382.
［19］	Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase 2 （TYK2） for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS⁃986165［J］. J Med Chem, 2019,62（20）:8973⁃8995. doi: 10.1021/acs.jmedchem. 9b00444.
［20］	Enerbäck C, Sandin C, Lambert S, et al. The psoriasis⁃protective TYK2 I684S variant impairs IL⁃12 stimulated pSTAT4 response in skin⁃homing CD4+ and CD8+ memory T⁃cells［J］. Sci Rep, 2018,8（1）:7043. doi: 10.1038/s41598⁃018⁃25282⁃2.
［21］	Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain［J］. Sci Transl Med, 2019,11（502）:eaaw1736. doi: 10.1126/scitranslmed.aaw1736.
［22］	Armstrong A, Gooderham M, Warren RB, et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 （TYK2） inhibitor, compared with placebo and apremilast in moderate to severe plaque psoriasis: results from the phase 3 POETYK PSO⁃1 study［J］. Ann Rheum Dis,2021, 80（Suppl 1）:795⁃796. doi: 10.1136/annrheumdis⁃2021⁃eular.1002.
［23］	Gerstenberger BS, Ambler C, Arnold EP, et al. Discovery of tyrosine kinase 2 （TYK2） inhibitor （PF⁃06826647） for the treatment of autoimmune diseases［J］. J Med Chem, 2020,63（22）:13561⁃13577. doi: 10.1021/acs.jmedchem.0c00948.
［24］	Fensome A, Ambler CM, Arnold E, et al. Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of （（S）⁃2,2⁃Difluorocyclopropyl）（（1 R,5 S）⁃3⁃（2⁃（（1⁃methyl⁃1 H⁃pyrazol⁃4⁃yl）amino）pyrimidin⁃4⁃yl）⁃3,8⁃diazabicyclo［3.2.1］octan⁃8⁃yl）methanone （PF⁃06700841）［J］. J Med Chem, 2018,61（19）:8597⁃8612. doi: 10.1021/acs.jmedchem. 8b00917.
［25］	Forman SB, Pariser DM, Poulin Y, et al. TYK2/JAK1 inhibitor PF⁃06700841 in patients with plaque psoriasis: phase IIa, randomized, double⁃blind, placebo⁃controlled trial［J］. J Invest Dermatol, 2020,140（12）:2359⁃2370.e5. doi: 10.1016/j.jid.2020. 03.962.
［26］	Vaclavkova A, Chimenti S, Arenberger P, et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double⁃blind, placebo⁃controlled phase 2 trial［J］. The Lancet, 2014, 384（9959）:2036⁃2045. doi: 10.1016/s0140⁃6736（14）60803⁃5.
［27］	Weisel K, Berger S, Papp K, et al. Response to inhibition of receptor⁃interacting protein kinase 1 （RIPK1） in active plaque psoriasis: a randomized placebo⁃controlled study［J］. Clin Pharmacol Ther, 2020,108（4）:808⁃816. doi: 10.1002/cpt.1852.
［28］	Cores Á, Piquero M, Villacampa M, et al. NRF2 regulation processes as a source of potential drug targets against neurodegenerative diseases［J］. Biomolecules, 2020,10（6）:904.doi: 10.3390/biom10060904.
［29］	Gao W, Guo L, Yang Y, et al. Dissecting the crosstalk between Nrf2 and NF⁃κB response pathways in drug⁃induced toxicity［J］. Front Cell Dev Biol, 2021,9:809952. doi: 10.3389/fcell.2021. 809952.
［30］	Swindell WR, Bojanowski K, Chaudhuri RK. Transcriptomic analysis of fumarate compounds identifies unique effects of isosorbide di⁃（methyl fumarate） on NRF2, NF⁃kappaB and IRF1 pathway genes［J］. Pharmaceuticals, 2022,15（4）:461. doi:10.3390/ph15040461.
［31］	Mrowietz U, Szepietowski JC, Loewe R, et al. Efficacy and safety of LAS41008 （dimethyl fumarate） in adults with moderate⁃to⁃severe chronic plaque psoriasis: a randomized, double⁃blind, Fumaderm®⁃and placebo⁃controlled trial （BRIDGE）［J］. Br J Dermatol, 2017,176（3）:615⁃623. doi: 10.1111/bjd.14947.
［32］	Cai L, Chen GH, Lu QJ, et al. A double⁃blind, randomized, placebo⁃ and positive⁃controlled phase III trial of 1% benvitimod cream in mild⁃to⁃moderate plaque psoriasis［J］. Chin Med J （Engl）, 2020,133（24）:2905⁃2909. doi: 10.1097/CM9. 0000000000001221.

[1]	Sun Jie, Wang Rui, Li Chengxin. Tumor necrosis factor-α inhibitor?induced psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 821-824.
[2]	Liu Jin, Shen Zhengyu. Epigenetic regulation in psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 825-829.
[3]	Xiao Chunying, Wang Gang. Roles of Langerhans cells in psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 830-834.
[4]	Zhou Xue, Yu Zengyang, Chen Youdong, Guo Chunyuan, Yu Qian, Hu Yifan, Yao Lingling, Shi Yuling, . Tumor necrosis factor α-mediated low expression of fatty acid desaturase 2 in psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 752-758.
[5]	Yao Lingling, Yu Zengyang, Guo Chunyuan, Zhou Jing, Cui Lian, Yu Qian, Yu Yingyuan, Zhou Xue, Cai Jiangluyi, Shi Yuling, . Changes in circadian gene cryptochrome 2 expression in mouse models of psoriasis and HaCaT cells and their underlying mechanisms [J]. Chinese Journal of Dermatology, 2022, 55(9): 759-766.
[6]	Zheng Jiayuan, Yu Bingqian, Chen Xianxia, Luo Zhicheng. Characteristics of pruritus in adult patients with psoriasis vulgaris and its effect on quality of life [J]. Chinese Journal of Dermatology, 2022, 55(9): 790-794.
[7]	Wang Lingyan, Pan Jing, Miao Gang, Chang Xiaodan, Jin Qiuzi, Guo Ningning, Zhang Jiayu. Analysis of difficult-to-treat sites in patients with psoriasis who received biological therapy [J]. Chinese Journal of Dermatology, 2022, 55(7): 583-587.
[8]	Committee on Autoimmune Diseases, China Dermatologist Association. Cyclosporine in the treatment of immune-related skin diseases: an expert proposal [J]. Chinese Journal of Dermatology, 2022, 55(6): 471-479.
[9]	Shan Ying, Zuo Yagang. Correlation between autoimmune bullous diseases and psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(5): 452-455.
[10]	Environmental and Occupational Skin Disease Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine, Group on Children, Chinese Society of Dermatology, Committee on Dermatology, Chinese Association of Geriatric Research. Expert consensus on rational application of topical agents and patient education for atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 281-288.
[11]	Wang Xiaowen, Li Ruoyu. Superficial fungal infections in psoriasis patients treated with IL-17 related biological agents and their management [J]. Chinese Journal of Dermatology, 2022, 55(3): 272-275.
[12]	Wang Zhaoyang, Chen Anwei, Xiang Xin, Luo Xiaoyan, Xu Zigang, Wang Hua, Ma Lin. An investigation into the current situation of pediatric psoriasis based on the information systems from two children′s hospitals [J]. Chinese Journal of Dermatology, 2022, 55(3): 246-250.
[13]	Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2022） [J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195.
[14]	Wang Yue, Yan Yulin. Analysis of adverse drug reactions and reasons for drug discontinuation during acitretin therapy in 171 patients with psoriasis vulgaris [J]. Chinese Journal of Dermatology, 2022, 55(3): 242-245.
[15]	Li Yan, Li Ming, Xu Wei, Li Linfeng. Efficacy of fluticasone propionate cream alone or in combination with calcipotriol ointment in the treatment of mild to moderate plaque psoriasis: a randomized self-controlled study [J]. Chinese Journal of Dermatology, 2022, 55(3): 260-263.

Small-molecule targeted agents: new choices for the treatment of psoriasis

PDF

Knowledge

Abstract

Cite this article

share this article

References ［32］

Related Articles 15

Metrics

Comments

Recommended 10